drotrecogin alfa

Ligand id: 6788

Name: drotrecogin alfa

No information available.
Summary of Clinical Use
In the USA drotrecogin was FDA approved for the reduction of mortality in adult patients with severe sepsis, but was withdrawn (2011) due to a failure to show a survival benefit for patients with severe sepsis and septic shock
Mechanism Of Action and Pharmacodynamic Effects
Endogenous activated protein C exerts its antithrombotic effect by inhibiting blood coagulation factors Va and VIIIa. Drotrecogin alfa (activated) acts in the same way to produce its anti-thrombotic, anti-inflammatory, and profibrinolytic properties.